tbuckley/cabot-search huggingface dataset:
BRONCHOSTENOSIS COMPLICATING ALLERGIC AND INFECTIOUS ASTHMA
Authors: Louis E. Prickman, Herman J. Moersch
Journal: Annals of Internal Medicine (1940)

Article1 September 1940BRONCHOSTENOSIS COMPLICATING ALLERGIC AND INFECTIOUS ASTHMALOUIS E. PRICKMAN, M.D., F.A.C.P., HERMAN J. MOERSCH, M.D., F.A.C.P.LOUIS E. PRICKMAN, M.D., F.A.C.P.Search for more papers by this author, HERMAN J. MOERSCH, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-3-387 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBronchostenosis is a much more common complication of either allergic or infectious asthma than is generally believed. By bronchostenosis is meant a definite, localized, stricture-like narrowing of a bronchus. The lesion is felt to be primarily inflammatory in nature, and not referable to allergic edema or bronchial spasm. Two outstanding disturbances of function result when a bronchus becomes stenosed; first, the movement of air entering or leaving the segment of pulmonary tissue beyond the region of the stenosis is inhibited, and second, bronchial secretions which usually are excessive in asthma, are retained below the stenotic region so that a region...References1. LEMONVINSONMOERSCHKIRKLIN WSPPHJBR: Primary carcinoma of the bronchus, Southwestern Med., 1932, xvi, 485-493. Google Scholar2. PRICKMANMOERSCH LEHJ: Bronchostenosis complicating allergic and infectious asthma, Med. Clin. N. Am., 1939, xxiii, 961-975. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, Minnesota*Read before the meeting of the American College of Physicians, Cleveland, Ohio, April 5, 1940. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie BronchiektasienThe enhancement of infection with staphylococcus aureus in mice sensitized by bovine serum-pertussis mixturesAsthma bronchialeRESPIRATORY ALLERGIES AND THEIR MODIFICATIONS IN PATIENTS OVER 45 YEARS OF AGE†EMPHYSEMA IN THE AGEDXCVI Hidden or Unsuspected Bronchiectasis in the AsthmaticLXXX Unusual Conditions Simulating Pulmonary AtelectasisCIV Recent Advances in Bronchology and in the Diagnosis and Treatment of Pulmonary DiseaseBronchoscopic therapy in allergic asthmaUSE AND ABUSE OF BRONCHOSCOPY IN ALLERGIC ASTHMAXCV Recent Advances in Otolaryngologic AllergyAllergy in otorhinolaryngology and ophthalmology. A review of the recent current literature 1 September 1940Volume 14, Issue 3Page: 387-392KeywordsAsthmaEdemaLesionsStenosis ePublished: 1 December 2008 Issue Published: 1 September 1940 PDF downloadLoading ...
World Medical Association ‘appalled’ at oral mutilation in parts of Africa
Authors: Chibuzo Odigwe
Journal: BMJ (2004)

The World Medical Association has called for an end to the traditional practice of oral mutilation of infants and has lent its voice to the call for improved dental care services in Africa.

The call was made last week in Nairobi by the association's president, James Appleyard, at the first ever planning conference for oral health in the African region.

He said, “One of the most appalling customs, referred to …
Tree pollen allergens—an update from a molecular perspective
Authors: C. Asam, H. Hofer, M. Wolf, L. Aglas, M. Wallner
Journal: Allergy (2015)

It is estimated that pollen allergies affect approximately 40% of allergic individuals. In general, tree pollen allergies are mainly elicited by allergenic trees belonging to the orders Fagales, Lamiales, Proteales, and Pinales. Over 25 years ago, the gene encoding the major birch pollen allergen Bet v 1 was the first such gene to be cloned and its product characterized. Since that time, 53 tree pollen allergens have been identified and acknowledged by the WHO/IUIS allergen nomenclature subcommittee. Molecule-based profiling of allergic sensitization has helped to elucidate the immunological connections of allergen cross-reactivity, whereas advances in biochemistry have revealed structural and functional aspects of allergenic proteins. In this review, we provide a comprehensive overview of the present knowledge of the molecular aspects of tree pollen allergens. We analyze the geographic distribution of allergenic trees, discuss factors pivotal for allergic sensitization, and describe the role of tree pollen panallergens. Novel allergenic tree species as well as tree pollen allergens are continually being identified, making research in this field highly competitive and instrumental for clinical applications.
Monitoring midline shift by transcranial color-coded sonography in traumatic brain injury
Authors: JuanAntonio Llompart Pou, JosepMar�a Abadal Centellas, Margarita Palmer Sans, Jon P�rez B�rcena, Marcial Casares Vivas, Javier Homar Ram�rez, Jorge Ib��ez Juv�
Journal: Intensive Care Medicine (2004)
France and United Kingdom Channel Efforts to Improve Health Services
Authors: R Voelker
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent
Authors: Francesco Mauri, Aldo Pietro Maggioni, Maria Grazia Franzosi, Claudio De Vita, Eugenio Santqro, Luigi Santoro, Pantaleo Giannuzzi, Gianni Tognoni
Journal: Journal of the American College of Cardiology (1994)
The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice
Authors: Shuaiying Cui, Kim-Chew Lim, Lihong Shi, Mary Lee, Natee Jearawiriyapaisarn, Greggory Myers, Andrew Campbell, David Harro, Shigeki Iwase, Raymond C. Trievel, Angela Rivers, Joseph DeSimone, Donald Lavelle, Yogen Saunthararajah, James Douglas Engel
Journal: Blood (2015)
Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study
Authors: W.-Q. Li, J.-L. Han, J.E. Manson, E.B. Rimm, K.M. Rexrode, G.C. Curhan, A.A. Qureshi
Journal: British Journal of Dermatology (2011)

Psoriasis has been linked to cardiovascular comorbidities in cross-sectional studies, but evidence regarding the association between psoriasis and incident cardiovascular disease (CVD) is limited.To make a prospective evaluation of the association between psoriasis and risk of incident nonfatal CVD.Participants (n = 96, 008) were included from the Nurses' Health Study II, and followed for 18 years. Information on physician-diagnosed psoriasis was obtained by self-report and diagnosis was confirmed by supplementary questionnaires. We included 2463 individuals with self-reported psoriasis and a subsample of 1242 with validated psoriasis. The main outcome was incident nonfatal CVD events [nonfatal myocardial infarction (MI) and nonfatal stroke], ascertained by biennial questionnaires and confirmed.During 1 709 069 person-years of follow-up, 713 incident nonfatal CVD events were confirmed. Psoriasis was associated with a significantly increased multivariate-adjusted hazard ratio (HR) of nonfatal CVD, 1·55 [95% confidence interval (CI): 1·04-2·31]. HRs for nonfatal MI and stroke were 1·70 (95% CI: 1·01-2·84) and 1·45 (95% CI: 0·80-2·65), respectively. The association remained consistent in a sensitivity analysis of confirmed psoriasis (HR: 2·06, 95% CI: 1·31-3·26). For individuals with concomitant psoriatic arthritis, the risk of nonfatal CVD was even higher (HR: 3·47; 95% CI: 1·85-6·51). Women diagnosed with psoriasis at < 40 years of age or with duration of psoriasis ≥ 9 years had substantial elevations in CVD risk: HR: 3·26 (95% CI: 1·21-8·75) and 3·09 (95% CI: 1·15-8·29), respectively.Psoriasis is an independent predictor for nonfatal CVD among women, with particularly high risk for those with longer duration of psoriasis and concomitant psoriatic arthritis.
858. Correction of the CNS Pathology and Function of MPS VII Mice by Intraventricular Transplantation of Genetically Modified Bone Marrow Stromal Cells
Authors: Ken Sakurai, Sayoko Iizuka, Jin Song Shen, Xing Li Meng, Taisuke Mori, Akihiro Umezawa, Toya Ohashi, Yoshikatsu Eto
Journal: Molecular Therapy (2004)

Mucopolysaccharidosis type VII (MPSVII) is one of lysosomal storage diseases (LSDs) and caused by a genetic deficiency of beta-glucuronidase (GUSB) resulting in the progressive accumulation of glycosaminoglycans(GAGs) in the brain and other tissues. Although current therapies for LSDs are enzyme replacement therapy and bone marrow transplantation, both therapies have various limitations especially in the brain. As an alternative approach, we transplanted genetically modified bone marrow stromal (BMS) cells into the lateral ventricle of neonatal MPSVII mice. The murine BMS cells transduced by a retroviral vector expressing human GUSB gene was injected into the lateral ventricle of newborn MPSVII mice. Two weeks after transplantation, the GUSB positive cells were identified in the olfactory bulb, cerebral cortex and striatum and the enzymatic activities in the various brain areas of treated mice increased about 50 times higher than untreated mice (0.15nmol/hr/mg protein to 7.81nmol/hr/mg protein). It is well known that alfa-Galactosidase A and Hexosaminidase activity in the brain for MPSVII is elevated. In treated mice, these enzymatic activities decreased to those of heterozygote mouse level. Although lysosomal distention in many neural cells and endothelial cells of untreated mice was observed, there was no lysosomal distention in the various brain regions of treated mice at 4 weeks of age. The amount of chondroitine sulfate and hyarulonic acid of GAGs which is known as storage material of MPSVII mice, were decreased significantly in treated mice. This reduction persisted at 16 weeks after transplantation. We performed the Morris Water Maze test (MWM) to evaluate the brain function of treated mice 6 weeks after transplantation. On day 6 of MWM, the platform was removed and the amount of time spent in each quadrant was monitored. Average of the time spent in the target quadrant by treated mice was 22.4 (sec), whereas average of the time spent by untreated mice was 18.2 (sec). Treated mice spent significantly more time in the target quadrant than in the mean of other three non-target quadrants (P=0.0028), whereas in untreated mice the difference of time spent in the target quadrant and the mean of the other three non-target quadrants was not statistically significant (P=0.3201). BMS cells have various advantages, including easy accessibility, minimum ethical issues and minimum immuno-reaction from the host. These data suggest that BMS cells are an excellent vehicle by which to transfer therapeutic protein to the brain in multiple lysosomal storage diseases.
Abstract 17: Hepatitis C virus (HCV) core protein potentiates proangiogenic activity of hepatocellular carcinoma (HCC) cells
Authors: Yu-Yun Shao, Chung-Yi Huang, Jun-Wei Chen, Chih-Hung Hsu, Ann-Lii Cheng
Journal: Cancer Research (2014)

Abstract Background: Recent clinical trials found that sorafenib may have better efficacy for HCV-related HCC than HCC with other etiologies. HCV core protein has been found to influence the mitogen-activated protein kinase pathway, which is one of the targets of sorafenib. We thus planned this study to examine the effect of HCV core protein overexpression on HCC cells. Methods: We stably expressed HCV core protein in Huh7, a HCC cell line, using a lentivirus based vector S2. Two stable clones were selected for experiments. One clone (Huh7-core-high) expressed a higher amount of HCV core protein than the other (Huh7-core-low). Huh7 expressing the empty vector (Huh7-S2) served as a control. We compared the cytotoxicity of sorafenib in these cells using the MTT assay. Tube formation analysis and Matrigel plug assay were performed to evaluate the angiogenic activity. Results: Huh7-core-high and Huh7-core-low cells did not show increased cell proliferation compared to Huh7-S2 cells. Sorafenib showed similar in vitro cytotoxicity for Huh7-core-high, Huh7-core-low, and Huh7-S2 cells. Overexpression of HCV core protein potentiates proangiogenic activity of Huh7 cells dose-dependently. In tube formation analysis, Huh7-core-high induced more potent angiogenesis than Huh7-S2 cells with more total tube lengths (p = 0.02), mean tube lengths (p = 0.04), mean tube areas (p = 0.04), branch points (p = 0.03), and nodes (p &amp;lt; 0.01). Huh7-core-low cells induced stronger angiogenesis than Huh7-S2 cells with more total tube lengths (p = 0.05) and branch points (p = 0.01). By Matrigel plug assay, Huh7-core-high and Huh7-core-low cells dose-dependently induced stronger angiogenesis in mice compared to Huh7-S2 cells with significantly higher hemoglobin levels in the Matrigel plugs. Conclusions: HCV core protein expression potentiates the proangiogenic activity of HCC, both in vitro and in vivo. (This work was supported by grants NSC98-3112-B-002-038, NSC101-2314-B-002-141, 100CAP1020-2 &amp; 102-2314-B-002-120.) Citation Format: Yu-Yun Shao, Chung-Yi Huang, Jun-Wei Chen, Chih-Hung Hsu, Ann-Lii Cheng. Hepatitis C virus (HCV) core protein potentiates proangiogenic activity of hepatocellular carcinoma (HCC) cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 17. doi:10.1158/1538-7445.AM2014-17
A heart-to-heart with Andrew R. Marks
Authors: Ushma S. Neill
Journal: Journal of Clinical Investigation (2010)

Adding to his many accolades, National Academy member and former JCI editor in chief Andrew R. Marks, of the Columbia University College of Physicians & Surgeons, will receive the ASCI’s annual prize, the Stanley J. Korsmeyer Award (Figure ​(Figure1).1). Marks receives the award in recognition of his discovery that rapamycin inhibits coronary artery stent restenosis and for showing the role of leaky ryanodine receptor/calcium release channels in heart failure, cardiac arrhythmias, and muscular dystrophy.
Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma
Authors: Kerry J. Savage, Samira Zeynalova, Roopesh R. Kansara, Maike Nickelsen, Diego Villa, Laurie H. Sehn, Marita Ziepert, David W. Scott, Michael Pfreundschuh, Randy D. Gascoyne, Joseph M. Connors, Bertram Glass, Markus Loeffler, Norbert Schmitz
Journal: Blood (2014)
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).
Authors: Thomas Cheung Yau, Wattana Sukeepaisarnjaroen, Yee Chao, Chia-Jui Yen, Wirote Lausoontornsiri, Pei-Jer Chen, Theeranun Sanpajit, Riccardo Lencioni, Aaron C Camp, Donna S Cox, Howard Kallender, Lone Harild Ottesen, Ronnie Tung-Ping Poon
Journal: Journal of Clinical Oncology (2012)

4108 Background: Hepatocyte growth factor (HGF)/MET signalling plays a pivotal role in tumor cell proliferation, migration and invasion in HCC and circulating levels of HGF correlate with poor prognosis. This phase I/II trial (MET111645) evaluated foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR, as first-line therapy in Asian advanced-HCC patients. Methods: Asian patients with measurable, unresectable/metastatic HCC, no prior sorafenib or other multi-kinase inhibitors, ECOG PS 0-1, adequate organ function and Child-Pugh grade A were recruited. The phase I was a standard 3+3 dose escalation design with a phase II cohort expansion. The primary endpoint was safety and tolerability at the maximum tolerated dose (MTD) and the secondary endpoints included antitumor activity (objective response rate [ORR], disease stabilization rate [DSR; confirmed CR/PR or SD for at least 12 weeks], and time to progression [TTP] evaluated by central review according to modified RECIST), and overall survival (OS) at the MTD, plus pharmacokinetics (PK). Results: Thirteen patients were enrolled in phase I. Two dose-limiting toxicities (DLT) (renal failure, proteinuria) were observed at 45 mg once daily (QD) but no DLTs were observed at 30 mg QD. Thus, the MTD was determined to be 30 mg QD. A further 32 patients were enrolled at the MTD, for a study total of 39 patients treated at 30 mg QD. The most common AEs, independent of causality,were hypertension (36%), decreased appetite (23%), and pyrexia (21%). The most common SAEs were hepatic encephalopathy (10%) and ascites (8%). Two patients discontinued foretinib due to AEs. No dose reductions were reported. Thirty-eight patients were evaluable for efficacy. The ORR was 24% (95% CI 11-40), DSR 79% (95% CI; 63-90), and the median TTP was 4.2 months (95% CI 2.7-7.5). Mature OS data will be presented. Mean steady-state exposures (AUC/Cmax) were comparable after administration of foretinib at 30 and 45 mg. Conclusions: Foretinib has an acceptable safety, tolerability, and PK profile in an Asian HCC population. It has demonstrated promising antitumor activity that warrants further testing in a randomized setting.
Could Fasting Plasma Glucose Be Used for Screening High-Risk Outpatients for Gestational Diabetes Mellitus?
Authors: Luiz Guilherme Kraemer de Aguiar, Haroldo José de Matos, Marília de Brito Gomes
Journal: Diabetes Care (2001)

The simplified oral glucose tolerance test (sOGTT) with 50 g is recommended for the screening of gestational diabetes mellitus (GDM) (1). However, because of the complexity of the test, the investigation of less expensive and easier methods to perform the screening has been extensively studied. Recently, in agreement with other studies (3), a population-based prospective study conducted on the general population of pregnant women in Brazil showed that fasting plasma glucose (FPG) was a good screening method for GDM (2).

With the purpose of determining an FPG value with good sensitivity and specificity that could identify pregnant women at risk for GDM, we conducted a study in 1994 with high-risk outpatient pregnant women in the State University Hospital of Rio de Janeiro, Brazil. During that year, 269 pregnant outpatients with at least one risk factor for GDM were included in the study. A screening test was performed on 261 pregnant women with 50 g of glucose load at …
Abstract 19787: Transcatheter Aortic Valve Implantation in Patients With Bicuspid Aortic Valve: a Patient Level Multi-center Analysis
Authors: Altayyeb Yousef, Trevor Simard, John Webb, Josep Rodés-Cabau, Charis Costopoulos, Janusz Kochman, José M Hernández-Garcia, Paul T Chiam, Robert C. Welsh, Harindra C. Wijeysundera, Eulogio García, Henrique B. Ribeiro, Azeem Latib, Zenon Huczek, Miriam Shanks, Luca Testa, Michael E. Farkouh, Danny Dvir, James L Velianou, Buu-Khanh Lam, Ali Pourdjabbar, Christopher Glover, Benjamin Hibbert, Marino Labinaz
Journal: Circulation (2014)

Objective: The purpose of the study was to determine the safety and efficacy of TAVI in patients with stenotic bicuspid aortic valve (BAV). Background: To date, patients with BAV have been excluded from major TAVI studies due to a theoretical increased risk of paravalvular leak (PVL). Data on the clinical performance of TAVI in these patients is limited. Methodology: We conducted a retrospective international multicenter cohort study of patients with BAV undergoing TAVI. The primary outcome of the study was the combined early safety endpoint - a composite of 30 day mortality, stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication and valve related dysfunction. Secondary endpoints included the individual components of the primary endpoint as well as post TAVI paravalvular leak (PVL), rehospitalization, new pacemaker insertion and device success rates at 30 days and 1 year. Results: A total of 107 patients with BAV were identified in 21 centers in Canada, Spain, Italy, Poland and Singapore who underwent TAVI between January 2005 and March 2014. The composite primary outcome occurred in one third of patients (28.6%) - mainly driven by re-intervention for valve malposition (12.3%). The 30-day and 1 year mortality rate was 9.7% and 17.2% respectively with AR ≥ 3+ occurring in 8.8% of patients. Device success was achieved in 85% of cases with pacemaker insertion in 17.9%. While PVL was not associated with an increased risk of 30 day or 1 year mortality - Type I BAV anatomy with left and right cusp fusion had significantly better outcomes than other variants. Conclusion: In selected patients with BAV and severe aortic stenosis TAVI appears both safe and feasible with acceptable clinical outcomes. A randomized comparison of TAVI versus surgical aortic valve replacement in this patient population is warranted.
32P Nucleotide Composition of Nuclear and Nucleolar RNA of Morris Hepatomas
Authors: Harris Busch, James L. Hodnett, Harold P. Morris, Rajat Neogy, Karel Smetana, Tadao Unuma
Journal: Cancer Research (1968)

Summary  Nuclei and nucleoli were isolated from a number of types of minimal deviation hepatomas. The nuclear preparations from hepatomas 9618A, 9618B, 9121, 9108A, 7794, and 7787 were equal in purity to those obtained from normal liver. The nuclear preparations from hepatomas 9098, R7, 8995, and others were similar to those obtained from tumors transplanted for long periods, i.e., the nuclear preparations contained perinuclear cytoplasmic tags. Nucleolar preparations of purity equal to those of normal liver and other tumors were obtained in sufficient yield for analysis of  32 P nucleotide compositions from hepatomas 9618A, 9618B, 9121, 9098, and 7787.  The  32 P nucleotide compositions of nuclear 45 S RNA of the Morris hepatomas varied from those rich in guanylic and cytidylic acids and low in adenylic acid, like those of the Walker tumor and other tumors transplanted for long periods, to those richer in adenylic acid and lower in cytidylic acid, which are more similar to the  32 P base compositions of nuclear 45 S RNA of regenerating liver.  The  32 P nucleotide compositions of the nucleolar 45 S RNA of the Morris hepatomas was like that of other tumors previously studied (28), i.e., the content of adenylic acid was low and the content of cytidylic acid was high. Along with the results of previous studies, these data suggest that there are common nucleotide compositions of the newly synthesized nucleolar RNA (45 S RNA) of tumor cells.